A phase III study of combination therapy with everolimus plus lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor (JCOG1901, STARTER-NET) ...

Survival disparities in small intestine carcinoid tumors: A SEER-based analysis. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include ...

Exelixis, Inc. (Nasdaq: EXEL) today announced results from a subgroup analysis of the phase 3 CABINET pivotal study of patients with extra-pancreatic ...

Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, ...

Small extracellular vesicles (sEVs ... They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatments. Now, researchers at the Perelman School of Medicine at the ...

Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Small Intestine Cancer. According to GlobalData, Phase II drugs for Small Intestine Cancer have a 100% ...

small intestine cancers are rare in the United States. In fact, they account for fewer than 1 in 10 cancers of the gastrointestinal (GI) tract, and fewer than 1 in 100 cancers overall. The American ...

The main challenge in diagnosing intestinal GTs is classifying the tumour as benign, malignant or of uncertain malignant potential. The diagnosis of MGTs is usually made according to Folpe’s study (26 ...

The tissue adjacent to a tumor behaves differently than areas farther away: The tumor’s cancerous cells influence their surroundings, blocking the body’s immune defenses and creating a sort of haven ...

1Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas. 2Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, ...